Journal
ARCHIVES OF GENERAL PSYCHIATRY
Volume 69, Issue 4, Pages 372-380Publisher
AMER MEDICAL ASSOC
DOI: 10.1001/archgenpsychiatry.2011.160
Keywords
-
Categories
Funding
- Analysis Group
- Bristol-Myers Squibb
- Eli Lilly and Co
- EPI-Q
- GlaxoSmithKline
- Johnson & Johnson Pharmaceuticals
- Ortho-McNeil Janssen Scientific Affairs
- Pfizer Inc
- sanofi-aventis
- Shire US Inc.
- National Institute of Mental Health [U01-MH60220, R01-MH66627, U01MH060220-09S1, R01-MH070884, R13-MH066849, R01-MH069864, R01-MH077883]
- Robert Wood Johnson Foundation [044780]
- John W. Alden Trust
- National Institute on Drug Abuse
- Fogarty International Center of the National Institutes of Health [FIRCA R03-TW006481]
- John D. and Catherine T. MacArthur Foundation
- Pfizer Foundation
- Pan American Health Organization
- AstraZeneca
- Ortho-McNeil
- Pfizer
- Wyeth
Ask authors/readers for more resources
Context: Community epidemiological data on the prevalence and correlates of adolescent mental disorders are needed for policy planning purposes. Only limited data of this sort are available. Objective: To present estimates of 12-month and 30-day prevalence, persistence (12-month prevalence among lifetime cases and 30-day prevalence among 12-month cases), and sociodemographic correlates of commonly occurring DSM-IV disorders among adolescents in the National Comorbidity Survey Replication Adolescent Supplement. Design: The National Comorbidity Survey Replication Adolescent Supplement is a US national survey of DSM-IV anxiety, mood, behavior, and substance disorders among US adolescents based on face-to-face interviews in the homes of respondents with supplemental parent questionnaires. Setting: Dual-frame household and school samples of US adolescents. Participants: A total of 10 148 adolescents aged 13 to 17 years (interviews) and 1 parent of each adolescent (questionnaires). Main Outcome Measures: The DSM-IV disorders assessed with the World Health Organization Composite International Diagnostic Interview and validated with blinded clinical interviews based on the Schedule for Affective Disorders and Schizophrenia for School-Age Children. Good concordance (area under the receiver operating characteristic curve >= 0.80) was found between Composite International Diagnostic Interview and Schedule for Affective Disorders and Schizophrenia for School-Age Children diagnoses. Results: The prevalence estimates of any DSM-IV disorder are 40.3% at 12 months (79.5% of lifetime cases) and 23.4% at 30 days (57.9% of 12-month cases). Anxiety disorders are the most common class of disorders, followed by behavior, mood, and substance disorders. Although relative disorder prevalence is quite stable over time, 30-day to 12-month prevalence ratios are higher for anxiety and behavior disorders than mood or substance disorders, suggesting that the former are more chronic than the latter. The 30-day to 12-month prevalence ratios are generally lower than the 12-month to lifetime ratios, suggesting that disorder persistence is due more to episode recurrence than to chronicity. Sociodemographic correlates are largely consistent with previous studies. Conclusions: Among US adolescents, DSM-IV disorders are highly prevalent and persistent. Persistence is higher for adolescents than among adults and appears to be due more to recurrence than chronicity of child-adolescent onset disorders.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available